Clinical Trials at Sentara Neurosciences Institute
At Sentara, we are committed to improving the lives of patients with neurological disorders. We know that having access to cutting edge trials and research studies focuses on finding new treatments are an important part of patient care.
For more information on these clinical trials and studies, please contact our Clinical Research Coordinator at 877-310-8713.
Clinical Research Studies at Sentara Neurosciences Institute
Learn more about our ongoing research studies in the following areas:
Advanced Parkinson’s Disease
Current research studies at Sentara focusing on advanced Parkinson’s disease include:
- A current clinical research study at Sentara Princess Anne Hospital will evaluate the effectiveness of an investigational drug compared to placebo (substance that has no therapeutic effect) in decreasing motor fluctuations.
- A clinical research study to evaluate the safety and effectiveness of an investigational medication compared to placebo (an inactive substance) in individuals with Parkinson's Disease who are experiencing hallucinations or delusions. The caregivers of participants with Parkinson's Disease and hallucinations or delusions, also play role in this study as their input is valuable. Individuals who wish to
participate must have experienced hallucinations or delusions for at least the past month.
Current research studies at Sentara focusing on epilepsy include:
- An investigational intranasal medication (USL261) is being studied in outpatients with partial or generalized epilepsy as a "rescue therapy" for the treatment of seizure clusters
- An 18-week study with patients who experience partial onset seizures and have had success with current anti-epileptic drugs (AEDs). The 18-week double-blind treatment period consists of a 2-week titration period, 6-week taper or conversion period, and a 10-week monotherapy period.
Current research studies at Sentara focusing on stroke treatment include:
• A study on insulin resistance intervention (IRIS) after stroke, sponsored by the National Institutes of Health, is examining a new therapeutic approach for stroke patients based on the detection and treatment of insulin resistance. Insulin resistance affects almost all patients with type II diabetes and 50 percent of non-diabetic patients with ischemic stroke. The IRIS trial will determine the effectiveness of a drug called pioglitazone, an agent used to reduce insulin resistance, for reducing the risk of stroke or MI (myocardial infarction or heart attack) among patients with a recent ischemic stroke or TIA (transient ischemic attack).
Atherothrombotic Ischemic Events
Current research studies at Sentara focusing on atherothrombotic Ischemic events include:
- Patients who have blockage in one or more arteries supplying blood to the heart, brain or legs can enroll in a study on secondary prevention of atherothrombotic Ischemic events. The study focuses on investigational drug that has not been approved for use by the health authorities or the U.S. Food and Drug Administration (FDA). The drug blocks platelets and may reduce the risk of heart attack or stroke. The purpose of the study is to test the safety and effectiveness of the drug, when used with standard medications. Such blockages are most commonly due to cholesterol deposits associated with atherosclerosis.
Arteriovenous Malformations (AVM)
Current research studies at Sentara focusing on arteriovenous malformations include:
- A National Institutes of Health sponsored study to determine whether it is better to treat an unruptured brain arteriovenous malformation (AVM) with one or more of several available procedures intended to eliminate the brain AVM or to rely on medical therapy to control symptoms.